FDA Gives Clovis Oncology's Rubraca a Priority Review

Sales of Clovis Oncology's (NASDAQ: CLVS) Rubraca could get a big lift just in time for summer. Today, the company told investors a supplemental application that could expand the addressable patient population of its lead drug will get a speedy review.